Hikma advances its epinephrine nasal spray with multi-market regulatory filings
Hikma advances its epinephrine nasal spray with multi-market regulatory filings — latest FDA regulatory news.
Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures, and markets a broad range of generic, branded, and injectable pharmaceutical products. It is a leading supplier of sterile injectable medicines in the U.S. and operates one of the largest generics businesses in the MENA region.
Company Info
Sector:Pharmaceutical / Generics and Injectables
Headquarters:London, United Kingdom (US operations: Berkeley Heights, NJ)
Founded:1978
Website:www.hikma.com/
Upcoming Milestones & Key Dates
Q2 2026
Earnings
Q1 2026 Earnings — Injectables franchise and Ohio expansion update
Late 2026
Manufacturing
First production from expanded Ohio facilities
Clinical Development Pipeline
Generic sterile injectable portfolio
Target: Various (small molecules and biologics)Generic oral solid pipeline
Target: Various (small molecules)Specialty injectables and biosimilars
Target: Various (biologics)Recent News
Hikma Outlines Plan to Invest $267M in Ohio Plants, Creating 350 Jobs
Hikma Pharmaceuticals announced a $267 million investment across its Ohio manufacturing facilities, expected to create 350 new jobs and expand sterile injectable and generic drug production capacity in the U.S. market.
Hikma outlines plan to invest $267M in Ohio plants, creating 350 jobs
Hikma outlines plan to invest $267M in Ohio plants, creating 350 jobs.